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Background and purpose — Previously, implant survival of 
total shoulder prostheses was reported to be inferior to that of 
hemiprostheses. However, the use of total prostheses has increased 
in Norway due to reported good functional results. On this back-
ground, we wanted to study implant survival of 4 major shoulder 
prosthesis types in Norway between 1994 and 2012.
Patients and methods — The study population comprised 4,173 
patients with shoulder replacements reported to the Norwegian 
Arthroplasty Register, including 2,447 hemiprostheses (HPs), 
444 anatomic total prostheses (ATPs), 454 resurfacing prosthe-
ses (RPs), and 828 reversed total prostheses (RTPs). Three time 
periods were compared: 1994–1999, 2000–2005, and 2006–2012. 
Kaplan-Meier failure curves were used to compare implant fail-
ure rates for subgroups of patients, and adjusted risks of revision 
were calculated using Cox regression analysis.
Results — For prostheses inserted from 2006 through 2012, 
the 5-year survival rates were 95% for HPs (as opposed to 94% 
in 1994–1999), 95% for ATPs (75% in 1994–1999), 87% for RPs 
(96% in 1994–1999), and 93% for RTPs (91% in 1994–1999). 
During the study period, the implant survival improved signifi-
cantly for ATPs (p < 0.001). A tendency of better results with acute 
fracture and worse results in sequelae after previous fractures 
was seen in all time periods. 
Interpretation — The 5-year implant survival rates were good 
with all prosthesis types, and markedly improved for anatomic 
total prostheses in the last 2 study periods. The better functional 
results with total shoulder prostheses than with hemiprostheses 
support the trend towards increased use of total shoulder pros-
theses. 

In a previous study from the Norwegian Arthroplasty Regis-
ter (NAR), we reported superior results in terms of prosthesis 
survival with shoulder hemiprostheses (HPs) than with total 
prostheses (TPs), both anatomic and reverse (Fevang et al. 
2009). However, several other studies have shown better func-
tional results with the use of TPs than with HPs (Bryant et al. 
2005, Pfahler et al. 2006, Radnay et al. 2007), and in a recent 
report from the NAR in which functional outcome was evalu-
ated, patients with HPs came out worst for all variables mea-
sured (Fevang et al. 2013). Based on these studies and treat-
ment practice in other countries, a change in treatment policy 
has taken place in Norway—towards reduced use of HPs and 
increasing use of TPs, both anatomic and reversed types. The 
increasing volume of shoulder arthroplasty surgery in general, 
and also the relative increase in the use of TPs compared to 
HPs, will undoubtedly have increased the experience of Nor-
wegian surgeons with shoulder arthroplasty surgery in gen-
eral and insertion of TPs in particular. With this background, 
we wanted to compare the results of shoulder arthroplasties 
in Norway over 3 time periods (1994–1999, 2000–2005, and 
2006–2012) in order to determine whether this change in 
treatment policy has improved results in terms of prosthesis 
survival for total prostheses. 
 
Patients and methods
The NAR started collection of data on shoulder prostheses in 
1994. All Norwegian hospitals performing shoulder arthro-
plasty surgery report to the registry and the completeness of the 
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operations and revisions, and the form filled in by the oper-
ating surgeon contains information on patient characteristics, 
diagnosis, and data regarding the surgery and implant. Data 
on death or emigration are obtained from Statistics Norway. 
More than 1 diagnosis may be recorded for each patient, but 
for the present study, each patient was allocated 1 diagnosis 
according to a system in which the diagnoses were ranked as 
follows: osteoarthritis (OA) which ranked lowest, rheumatoid 
arthritis (RA), fracture sequelae (FS), and acute fracture (AF) 
which ranked highest. The outcome in this study was prosthe-
sis survival or failure. We did not evaluate functional results.
As the aim of this study was to compare the results of 4 
major prosthesis categories within 3 time periods, only 
patients with the 4 most frequent diagnoses (OA, RA, FS, and 
AF) were included in order to obtain comparable homogenous 
patient groups. Patients in whom the shoulder arthroplasty 
was inserted due to a malignant tumor were excluded (n = 19). 
Furthermore, 346 patients with the following diagnoses were 
excluded: rotator cuff arthropathy (n = 109), sequela after lig-
ament damage (n = 39), sequela after dislocation (n = 21), pso-
riatic arthritis (33), ankylosing spondylitis (21), osteonecrosis 
(n = 24), sequela after infection (n = 19), and other diagnosis 
(n = 80). Additionally, 83 patients were excluded because of 
missing values for one of the crucial variables (patient char-
acteristics, date of surgery, type of prosthesis, or outcome). 
Eventually, 4,173 patients (3,166 women (76%) and 1,007 
men (24%)) remained for inclusion, 1,398 with OA, 811 with 
RA, 787 with FS, and 1,177 with AF.
Patients were followed from their primary arthroplasty until 
revision, death, emigration, or end of follow-up (December 31, 
2012). In order to study a possible change in results according 
to change in treatment policy, the patients were divided into 3 
groups according to the year of primary surgery: 1994–1999, 
2000–2005, and 2006–2012 (Table 1). Furthermore, they were 
grouped according to prosthesis type: hemiprosthesis (HP, n 
= 2,447), anatomic total prosthesis (ATP, n = 444), resurfac-
ing prosthesis (RP, n = 454)—which were all hemiprosthe-
ses—and reversed total prosthesis (RTP, n = 828) (Table 1 and 
Figure 1). Several different prosthesis brands were used and 
the complete list can be found in the 2012 annual report from 
the NAR: http://nrlweb.ihelse.net/Rapporter/Rapport2013.
pdf.
Type of fixation was registered in all but 149 cases, which 
were excluded from the analysis addressing prosthesis fixa-
tion (Table 1 and Figure 4). The term hybrid fixation refers 
to implant fixation where one component is inserted using 
cement and the other without cement. In 2006–2012, most 
RTPs were inserted with cementation of the humeral compo-
nent without cementation of the glenoid component. Separate 
survival analyses were done comparing type of fixation for 
each prosthesis type within each of the 3 time periods. These 
figures are not presented, but some results are given. For TPs, 
the term Global denotes a combination of a Global cup and 
Global Advantage stem. 
Statistics
We used unadjusted Kaplan-Meier failure plots to illustrate 
differences in prosthesis failure between patients operated 
during the 3 different time periods for each of 4 different pros-
thesis types (Figure 2). Cumulative failure between the pros-
thesis types within 1 of 3 given time periods was compared 
(Figure 3) and plots according to mode of fixation were esti-
mated for each prosthesis type (Figure 4).  Since the prosthesis 
brands differed to some extent between the 3 study periods, 
separate analyses were performed comparing the most com-
monly used brands of each prosthesis type (Figure 5). 
We used Cox regression to analyze the risk of revision for 
the total study period (Table 4) and within 3 different time 
periods, with adjustment for age, sex, diagnosis, and prosthe-
sis type (Table 5). Method of fixation (cemented, uncemented, 
or hybrid) was not included in the regression analysis, as the 
impact of this variable is different for each prosthesis type. 
Instead, Kaplan-Meier failure plots illustrating the impact of 
fixation are presented (Figure 4). For RTPs, only patients with 
uncemented or hybrid fixation were included in the analysis 
because the number of cemented RTPs was low (n = 35).
Table 1. Sex, age, and mode of fixation during 3 time periods for 
hemiprostheses (HPs), anatomic total prostheses (ATPs), resurfac-
ing prostheses (RPs), and reversed total prostheses (RTPs)
Variable HP ATP RP RTP
 Time period n = 2,447 n = 444 n = 454 n = 828
Sex, % women 
 1994–1999, n = 737 80 84   71 82
 2000–2005, n = 981 81 45   73 85
 2006–2012, n = 2,455 77 61   57 81
Mean age (SD) 
 1994–1999, n = 737 68 (12) 70 (9.3)   64 (15) 67 (11)
 2000–2005, n = 981 71 (11) 64 (14)   68 (11) 71 (11)
 2006–2012, n = 2,455 72 (11) 68 (9.1)   64 (12) 73 (9.4)
Fixation, % a
 1994–1999
        Cemented 48 31   98 b   1
        Uncemented 52 65     2 96
        Hybrid  –   4   –   3
 2000–2005
    Cemented 70 33     0 11
    Uncemented 30 59 100 b 59
    Hybrid  –   8   – 30 
 2006–2012
    Cemented 75 65     1   4
    Uncemented 25 18   99 b 40
    Hybrid  – 17    – 56 c
HP: hemiprosthesis; ATP: anatomic total prosthesis; RP: resurfacing 
prosthesis; RTP: reversed total prosthesis.
a Percentage of HPs, TPs, RFs, and RTPs that were cemented, 
uncemented, or hybrid/inverse hybrid.
b In the period 1994–1999, only Scan resurfacing prostheses were 
used and they were all cemented. After this, the Scan prostheses 
were not used and the new resurfacing prostheses were mainly 
uncemented. 
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Results
During the study period, there was a change in treatment 
policy in Norway from almost exclusive use of hemiprosthe-
ses to increasing use of anatomic and reverse total prostheses 
(Figure 1). This development was seen in patients with all 4 
major diagnoses, but to a lesser degree in patients with AF 
(Table 2). 
For patients with RA or fracture sequelae, the use of RTPs 
in particular increased, while for those with osteoarthritis, an 
increasing use of ATPs was seen. For HPs and RTPs, there 
was an increase in patient age at the time of surgery, but this 
was not seen for ATPs and RPs (Table 1). Prosthesis fixation 
also changed, with increasing use of cementation for HPs and 
ATPs. For the RTPs, a change took place from almost exclu-
sive use of uncemented fixation during the first time period to 
mostly hybrid fixation in the last time period (Table 1). The 
cemented Scan prosthesis was the only resurfacing prosthe-
sis used in 1994–1999. After this, the use of Scan prostheses 
ceased and the new RPs were uncemented (Table 1).
Prosthesis survival
When we analyzed all the prosthesis types together, the pros-
thesis survival remained unchanged during the study period 
(Table 3). Also, in the overall study period, those patients with 
AF had the lowest risk of revision, RA and OA patients had 
similar results, while FS patients had a 1.5 times higher risk of 
revision than OA patients (p = 0.008) (Table 3). Furthermore, 
in the overall analysis RPs and RTPs had worse results than 
HPs and ATPs, which had similar results (Table 3). 
For prostheses inserted in the period 1994–1999, the 5-year 
cumulative survival rate for HPs was 94%; that for ATPs was 
75%, that for RPs was 96%, and that for RTPs was 91%. The 
5-year survival figures were as follows for prostheses inserted 
in the period 2006–2012: 95% for HPs, 95% for ATPs, 87% 
for RPs, and 93% for RTPs.
During the study period, a trend of improvement in results 
was seen for HPs (Figure 2) while the prosthesis survival 
improved markedly for ATPs (p < 0.001) (Figure 2). A trend 
of increased prosthesis failure was seen for RPs (Figure 2), 
while no significant change in prosthesis failure was detected 
for RTPs (Figure 2). 
Table 2. Percentage of patients with a given diagnosis having the 4 
different prosthesis types inserted, over 3 time periods
Diagnosis, % a HP ATP RP RTP Total
 Time period n = 2,447 n = 444 n = 454 n = 828 n = 4,173
Osteoarthritis
 1994–1999 72 13 6 9 119
 2000–2005 54 7 27 12 291
 2006–2012 25 33 20 23 988
Rheumatoid arthritis
 1994–1999 67 3 11 20 334
 2000–2005 58 2 15 25 197
 2006–2012 24 8 23 46 280
Acute fracture
 1994–1999 96 0 3 1 152
 2000–2005 99 0 0 1 274
 2006–2012 86 1 0 13 751
Fracture sequelae      
 1994–1999 80 6 6 8 132
 2000–2005 81 2 6 11 219
 2006–2012 47 8 5 39 436
For abbreviations, see Table 1.
a Percentage of patients with a given diagnosis during one of 3 time 
periods, who had a HP, ATP, RP, or RTP. 
Figure 1. Numbers of prostheses each year from 1994 through 2012
Table 3. Overall survival and risk of revision according to major 
explanatory factors 
Variable Category S5 a S10 a RR 95% CI p-value
Gender 
 Male 90 85 1  
 Female 93 90 0.8 0.6–1.0 0.08
Age, years 
 19–69 90 85 1  
 ≥ 70  95 93 0.6 0.5–0.7 < 0.001
Diagnosis 
 OA 91 87 1  
 RA 92 88 0.9 0.7–1.3 0.6
 AF 97 96 0.5 0.3–0.8 0.002
 FS 88 85 1.5 1.1–2.1 0.008
Prosthesis  
 HP 94 91 1  
 ATP 92 87 1.3 0.9–2.1 0.2
 RP 88 83 1.7 1.2–2.4 0.001
 RTP 92 85 1.7 1.3–2.3 0.001
Time period 
 1994–1999 93 89 1  
 2000–2005 92 89 1.0 0.7–1.4 1.0
 2006–2012 93 - 0.9 0.6–1.2 0.4
OA: osteoarthritis; RA: rheumatoid arthritis; AF: acute fracture; FS: 
fracture sequela; HP, ATP, RP, RTP: see Table 1.
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When comparing results for the 4 prosthesis types within 
each time period, the cumulative failure rate was much higher 
for ATPs than for the other prosthesis types in 1994–1999 (p < 
0.001) (Figure 3). For the period 2000–2005 (Figure 3), there 
was no difference in prosthesis failure, while for prostheses 
inserted in 2006–2012, the RPs fared significantly worse (p 
< 0.001) (Figure 3). Similarly, in the adjusted analyses (Table 
well (Table 5) (p < 0.001 for comparison of causes of revision 
between the prosthesis types). 
Furthermore, factors that had an impact on prosthesis failure 
changed throughout the study period (Table 4). Patients aged 
70 years or more had a lower rate of revision than the younger 
age group in 1994–1999 and 2000–2005 (RR = 0.6 and 0.45, 
respectively), but in the last time period the trend was simi-
Figure 2. Failure curves for 3 time periods, for each prosthesis type. 
Figure 3. Prosthesis failure, comparing 4 prosthesis types in 3 time periods.
4), there was a marked improvement in 
the survival of ATPs, as the failure rate 
was 4 times that of HPs in the first time 
period (RR = 4.5 for TPs compared to 
HPs) (Table 4), while the risk estimates 
were the same for these prosthesis types 
in the last 2 study periods (RR = 1.0). For 
RTPs, the risk of revision was higher in 
the first and last study periods (compared 
to HPs), but the relative risk was some-
what lower in the last study period (RR 
= 1.7 for 2006–2012 and RR = 2.4 for 
1994–1999). Furthermore, the RPs had 
a 2-fold increased risk of revision com-
pared to HPs in 2006–2012 (RR = 2.4; p 
= 0.001) (Table 4). 
Causes of and risk factors for 
implant failure
The most common causes of revision 
were pain, dislocation, implant loosen-
ing, instability, and deep infection (Table 
5). Some differences in the patterns of 
revision causes were seen for the 4 pros-
thesis types. The ATPs were especially 
subject to prosthesis dislocation. Gle-
noid loosening and deep infection were 
most frequent in RTPs, and the HPs and 
RPs were most often revised due to pain, 
although dislocation and instability were 
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lar but not statistically significant (RR = 0.7 for the older age 
group compared to the younger one; p = 0.1) (Table 4). A 
tendency of better prognosis in acute fracture (AF) patients 
and worse prognosis in patients with sequelae after previous 
fractures (FS) was seen in all time periods, but was only statis-
tically significant for patients with AF in 2000–2005 and for 
patients with fracture sequelae in the last time period (2006–
2012) (Table 4).
 In patients with HPs, the best results were seen when the 
prostheses were cemented (Figure 4). This was seen for HPs 
in all 3 time periods, but it was statistically significant only in 
the last 2 periods (p = 0.07, 0.01, and 0.005 for 1994–1999, 
2000–2005, and 2016–2012, respectively). While there was a 
similar trend of worse results for uncemented prostheses in 
the 3 other prosthesis types (Figure 4), no statistically signifi-
cant differences were seen—although RTPs with hybrid fixa-
tion appeared to fare better than uncemented ones (p = 0.08) 
(Figure 4D). In the analyses of each study period, no signifi-
cant differences in survival were seen for ATPs with the differ-
ent types of fixation (p = 0.51, 0.69, and 0.85 for the periods 
1994–1999, 2000–2005, and 2016–2012, respectively). 
Impact of prosthesis brand
To investigate whether the differences in results were due 
to prosthesis brands that were particularly superior, separate 
analyses were performed for the most commonly used brands 
of each prosthesis type (Figure 5). There was no great differ-
ence in survival for the 5 most commonly used hemiprosthe-
ses, but better results were seen with the most recently used 
ATPs, Aequalis and Global (p < 0.001), than with brands used 
in the earlier periods. A separate analysis comparing only 
prostheses inserted from 2002 and later revealed the same, 
with statistically significantly better results for the Aequalis 
and Global than for the Bio-Modular (analysis not shown), 
and the use of the Bio-Modular had almost ceased in the last 
study period (only 6 cases). No significant differences were 
seen for the most common resurfacing prosthesis brands and 
reversed prosthesis brands (Figure 5C and D). 
discussion
The main finding of this study was a marked improvement in 
prosthesis survival for anatomic total shoulder prostheses. A 
change towards older patients and more cemented prostheses 
may partly explain this improvement. Furthermore, new pros-
thesis types that were used in the last 2 study periods gave 
markedly better results. However, the improved results may 
also have been caused by a positive learning curve among the 
operating surgeons performing more ATPs in general. This 
finding contrasts that of our previous article evaluating shoul-
Table 4. Risk of revision during 3 time periods according to major 
explanatory factors 
Time period  Variable  Category RR 95% CI p-value
1994–1999 
 Sex Male 1
  Female 0.8 0.5–1.4 0.5
 Age, years 19–69 1
  ≥70 0.6 0.3–0.9 0.02
 Diagnosis OA 1
  RA 1.0 0.5–2.0 0.9
  AF 0.5 0.2–1.5 0.2
  FS 1.2 0.6–2.6 0.6
 Prosthesis  HP 1 
  ATP 4.5 2.3–9.0 < 0.001
  RP 1.2 0.5–2.8 0.7
  RTP 2.4 1.4–4.1 0.002
2000–2005 
 Sex Male 1
  Female 0.9 0.6–1.5 0.8
 Age, years 19–69 1 
  ≥70 0.45 0.3–0.7 0.001
 Diagnosis OA 1
  RA 0.7 0.4–1.2 0.2
  AF 0.4 0.2–0.8 0.008
  FS 1.3 0.8–2.2 0.3
 Prosthesis  HP 1  
  ATP 1.0 0.3–2.8 1.0
  RP 1.3 0.7–2.2 0.5
  RTP 1.2 0.6–2.2 0.6
2006–2012 
 Sex Male 1
  Female 0.7 0.5–0.99 0.05
 Age, years 19–69 1  
  ≥70 0.7 0.5–1.1 0.1
 Diagnosis OA 1
  RA 1.0 0.6–1.8 0.9
  AF 0.6 0.3–1.2 0.2
  FS 1.9 1.2–2.9 0.008
 Prosthesis  HP 1
  ATP 1.0 0.5–1.9 1.0
  RP 2.4 1.4–4.1 0.001
  RTP 1.7 1.0–2.8 0.03
For abbreviations, see Table 3.
Table 5. Causes of revision for the 4 major prosthesis types
 HP ATP RP RTP
 n = 2,447 n = 444 n = 454 n = 828
Loosening glenoid - 6 - 24
Loosening humerus 14 1 7 12
Dislocation 19 11 2 19
Instability 18 3 5 6
Deep infection 12 1 3 11
Pain 81 7 43 4
Other a 39 3 14 7
Total b 147 29 57 67
For abbreviations, see Table 1.
a Including worn polyethylene insert, periprosthetic fractures, axis 
deviation, dysfunction, and other.
b Total number of revisions within each prosthesis group. More than 
one cause of revision could be registered for each patient, giving a 
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Figure 4. Prosthesis failure according to type of fixation, for each prosthesis type.
der prosthesis survival, where failure rates of total prostheses 
were found to be high (Fevang et al. 2009). Cochrane reviews 
(Bryant et al. 2005, Singh et al. 2010) and reports from our 
own studies (Fevang et al. 2012, Fevang et al. 2013) show-
ing  superior functional results with ATPs may have contrib-
uted to the increasing use of such prostheses in Norway. This 
has most likely resulted in improvements in surgical experi-
ence and skills with these prostheses, ultimately leading to 
improved implant survival.  
A marked change in mode of fixation from 31% to 65% 
cementation was seen for ATPs. Although we were unable to 
detect a statistically significant effect of fixation type on sur-
vival of ATPs, even in the sub-analyses for each time period, 
it is noteworthy that the change in type of fixation coincided 
with the improvement in survival results.  
The Aequalis and Global ATPs gave better results than the 2 
other most frequently used ATP brands in the study. This could 
be due to frequent use (n = 192 for Aequalis as compared to 42 
for Bio-Modular) and consequent improved surgical experi-
ence with the prostheses, or it could be due to superior implant 
quality. The use of these prostheses in the last study period 
may have contributed to the increased survival of ATPs in that 
study period. 
lund and Nyberg 2011, Young et al. 2011) and we recently 
found that reversed prostheses  resulted in less pain and better 
function than anatomic total prostheses and hemiprostheses 
in RA patients (Fevang et al. 2013). In accordance with these 
publications, we found a marked increase in the use of RTPs 
in patients with RA in the present study.
The implant failure rate was somewhat higher for RTPs 
than for HPs in the first and last study periods (Table 5). One 
reason for the higher failure rate with RTPs may be that they 
might have been selected for patients with shoulders that were 
particularly badly damaged. Adjusting for diagnosis in the 
regression analysis may only control for this to some extent, 
as these prostheses are used in patients with injured rotator 
cuffs, irrespective of diagnosis. Even among patients with OA 
an increasing use of RTPs was seen, probably comprising OA 
patients with particularly ruined shoulders. Rotator cuff dis-
ease has previously been shown to be a risk factor for revi-
sion after total shoulder arthroplasty (Singh et al. 2011). In 
addition, RTPs inserted in our last study period had excellent 
5-year results, particularly the Delta Xtend, but as RTPs have 
previously had inferior long-term results, these new prosthe-
sis types must be followed up further. Taking into account the 
probably worse preoperative status of RTP shoulders and the 
In a study of patients who were oper-
ated from 1995 through 2005, no statis-
tically significant difference in implant 
survival rate was seen between total 
prostheses and hemiprostheses (Farng 
et al. 2011). The 5-year implant survival 
for both TPs and HPs was around 93% 
in that study, closely resembling the 
values in our study (94% for HPs and 
92% for ATPs) (Table 4). Furthermore, 
the 5-year survival of ATPs during our 
last study period (95%) compares well 
with that reported by Singh et al. (2011), 
although their 10-year estimate (90%) 
was better than the overall 10-year sur-
vival in our study (87%) (Table 4). 
Destruction of the glenohumeral joint 
is often accompanied by rotator cuff 
damage in patients with RA. In such 
patients, the insertion of ATPs or HPs is 
often followed by secondary rotator cuff 
failure and subsequent proximal humeral 
migration (Sneppen et al. 1996, Stewart 
and Kelly 1997, Betts et al. 2009). Thus, 
in these patients, ATPs have not been 
shown to give better functional results 
than hemiprostheses (Trail and Nuttall 
2002, Sperling et al. 2007). However, 
good results with the use of RTPs have 
been demonstrated in RA patients (Hol-
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Figure 5. Prosthesis failure according to brand, for each prosthesis type.
good functional results, there appears to be good reasons to 
continue the use of RTPs in the right patients—mainly RA and 
FS patients with rotator cuff damage—in whom good func-
tional results using RTP have been demonstrated (Fevang et 
al. 2013). 
Failure rates for resurfacing prostheses appeared to be 
higher in the last study period (Figure 2), and compared to 
HPs the difference in revision risk increased (RR = 2.4 for RPs 
vs. HPs in the last study period). Although 48 patients had an 
RP inserted in the last study period, the year-by-year figure 
shows a fall in the use of these prostheses after 2006 (Figure 
1). One explanation for the worsening of results for this pros-
thesis type may therefore be decreasing volume per surgeon 
as other and better prosthesis types are increasingly preferred. 
The results for hemiprostheses in terms of implant sur-
vival were good during the whole study period. Even so, 
inferior results for pain and function have been demonstrated 
in patients with HPs, and the high rate of revisions due to 
pain shown in this study reflects the same problem. With the 
improved implant survival of ATPs shown in the last 7-year 
period, we expect that the use of HPs will continue to fall and 
that more ATPs will be used. 
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